Keywords: medimmune, licenses, reverse, genetics, technology, gsk, cancer
MedImmune licenses reverse genetics technology to GSK
Article | 27 September 2007
US cancer and infectious and inflammatory diseases specialist MedImmune, which was recently purchased by AstraZeneca for $15.6 billion (Marketletters passim), says ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
